■ Researchers led by Thomas W. Samuelson, MD, used 2 different quality-of-life (QOL) questionnaires to determine how patients who had participated in the iStent inject (Glaukos) pivotal trial and another group that had cataract surgery alone viewed their QOL improvement. A total of 505 patients were randomized (n=386 iStent inject, n=119 surgery alone). The iStent inject group exhibited a greater percentage of positive responders across all follow-up visits over 24 months, averaging 58.0% vs 45.8 for VFQ-25 composite scores and 56.7% vs 48.9% for OSDI composite scores. Odds of being a responder in the iStent inject group were 60% higher for the VFQ-25 and 32% higher for the ODSI. Driving (49.0% vs 28.8%), ocular pain (59.3% vs 47.2%), and general vision (71.8% vs 60.0%), were the VFQ-25 subscales responsible for differences between treatment groups. At month 24, 76.5% of VFQ-25 responders and 62.5% of nonresponders were medication free regardless of treatment group.